Which GLP-1 drugs lead on weight loss
A network meta-analysis of phase 3 trials in adults without diabetes found all three major GLP-1 era weight-loss drugs reduced weight vs placebo, with higher-dose tirzepatide ranking highest on average.
If you spend any time in the obesity and weight-loss conversation, you run into the same practical question: which of the major drugs tends to deliver the largest average weight loss. A new systematic review and network meta-analysis tries to answer that using a deliberately narrow slice of evidence: phase 3 randomized trials in adults with obesity or overweight without type 2 diabetes.
The paper is Weight Loss With GLP‑1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‑Analysis (Obesity, 2026).
What they compared
The analysis focused on three therapies that define the “GLP‑1 era” of obesity treatment, even though they are not all identical in mechanism: semaglutide, liraglutide, and tirzepatide. The authors searched the literature through May 2025 and included 15 phase 3 randomized controlled trials, totaling 14,059 participants.
Network meta-analysis is designed for exactly this situation. When not every drug has been tested head-to-head against every other drug, the method estimates how treatments stack up by using placebo-controlled trials as a shared reference point.
What they found
Across the included trials, all three agents reduced weight versus placebo. In the authors’ ranking, the largest average reduction was associated with higher-dose tirzepatide, followed by semaglutide 2.4 mg, with liraglutide 3 mg generally ranking lower for weight loss.
They also reported a familiar tradeoff in their safety summaries: tirzepatide and semaglutide were associated with a higher risk of any adverse event compared with placebo, while liraglutide was not in their summary.
Why this is useful, and what it still cannot answer
This kind of paper is useful because it gives a clean, evidence-forward map of “how these stack up on average” using phase 3 trial data. It can also help cut through a common confusion in public discourse, where brand names and anecdotes blur together into something that feels like one big category of “weight-loss shots.”
But it is still a statistical comparison across trials with different populations, dosing schedules, and study designs. It will not settle the questions that matter most in real life: who discontinues, who regains weight, how outcomes look over longer timelines, and how different side effect patterns change what people will actually tolerate.
It is also a reminder of something easy to lose in peptide hype cycles. These are peptide-based (or peptide-adjacent) drugs with real clinical outcomes, but they still live inside normal medical constraints: access, monitoring, side effects, and what happens after the first dramatic year.